ExodusPoint Capital Management LP Sells 537,938 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD)

ExodusPoint Capital Management LP cut its stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 65.8% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 279,069 shares of the biopharmaceutical company's stock after selling 537,938 shares during the period. ExodusPoint Capital Management LP owned 0.09% of Amicus Therapeutics worth $2,629,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the company. R Squared Ltd bought a new position in shares of Amicus Therapeutics in the 4th quarter worth about $79,000. KBC Group NV increased its holdings in Amicus Therapeutics by 44.4% in the fourth quarter. KBC Group NV now owns 10,154 shares of the biopharmaceutical company's stock worth $96,000 after purchasing an additional 3,120 shares in the last quarter. Sciencast Management LP acquired a new position in Amicus Therapeutics in the fourth quarter valued at approximately $100,000. Stephens Inc. AR acquired a new position in Amicus Therapeutics in the fourth quarter valued at approximately $101,000. Finally, AlphaQuest LLC boosted its holdings in shares of Amicus Therapeutics by 635.1% during the 4th quarter. AlphaQuest LLC now owns 10,732 shares of the biopharmaceutical company's stock worth $101,000 after buying an additional 9,272 shares in the last quarter.

Amicus Therapeutics Stock Down 0.5 %

Shares of FOLD stock traded down $0.03 during trading hours on Friday, reaching $6.48. The company had a trading volume of 3,810,888 shares, compared to its average volume of 2,600,124. The business has a fifty day simple moving average of $8.71 and a 200-day simple moving average of $9.65. Amicus Therapeutics, Inc. has a 12 month low of $6.20 and a 12 month high of $12.65. The company has a market cap of $1.99 billion, a price-to-earnings ratio of -36.00, a price-to-earnings-growth ratio of 1.51 and a beta of 0.79. The company has a debt-to-equity ratio of 2.01, a current ratio of 3.39 and a quick ratio of 2.42.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on FOLD. Needham & Company LLC reiterated a "hold" rating on shares of Amicus Therapeutics in a research report on Thursday, February 20th. Wells Fargo & Company dropped their price objective on shares of Amicus Therapeutics from $18.00 to $17.00 and set an "overweight" rating on the stock in a report on Thursday, February 20th. StockNews.com downgraded Amicus Therapeutics from a "buy" rating to a "hold" rating in a research note on Thursday, February 20th. Morgan Stanley reaffirmed an "equal weight" rating and set a $12.00 price target (down from $17.00) on shares of Amicus Therapeutics in a research note on Friday, December 13th. Finally, Cantor Fitzgerald reiterated an "overweight" rating and issued a $21.00 price target on shares of Amicus Therapeutics in a report on Wednesday, January 15th. Three equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $16.75.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.